UBS Group’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
UBS Group's MDGL Position: Q3 2026 in Review
UBS Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 49% in Q3 2026, selling an estimated $104M and leaving 204,392 shares worth $103M. The position accounts for 0.01% of the portfolio, ranked #1076.
UBS Group first reported a position in MDGL in Q4 2014 and has held it in 47 quarters since. The position peaked at $216M in Q2 2026. 442 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- UBS Group held 204,392 shares of Madrigal Pharmaceuticals worth $103M as of Q3 2026.
- UBS Group sold 197,316 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $104M.
- Madrigal Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q3 2026, its #1076 holding.
- UBS Group first reported a position in Madrigal Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Madrigal Pharmaceuticals position peaked at $216M in Q2 2026.
- 442 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.